Neuronal tissue is the recently developed method for therapeutic uses. Some these methods patented are given below.
In Patent no: 6,233,480 titled ‘Methods and apparatus for optically imaging neuronal tissue and activity’ with the abstract : The present invention provides a method and apparatus for distinguishing neuronal tissue from surrounding tissue, for distinguishing functional neuronal tissue from dysfunctional tissue, and for imaging of functional neuronal areas in cerebral cortex by detecting changes in the optical properties of the neuronal tissue following stimulation of neuronal activity.
Patent no: 6,969,702 titled ‘Compounds and methods for increasing neurogenesis’ with the abstract : The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis increasing agents. Novel methods for treating neurological disorders using neurogenesis increasing agents are disclosed.
Patent no: 6,767,738 titled ‘Method of isolating adult mammalian CNS-derived progenitor stem cells using density gradient centrifugation’ with the abstract: The present invention is directed to methods of repairing damaged or diseased, specialized or differentiated tissue in mature animals, particularly neuronal tissue such as retinas. In particular, the invention relates to transplantation of adult, hippocampus-derived progenitor cells into a selected neural tissue site of a recipient. These cells can functionally integrate into mature and immature neural tissue. The invention encompasses, in one aspect, repopulating a retina of a dystrophic animal with neurons, by injecting clonally derived, adult central nervous system derived stem cells (ACSC) derived from a healthy donor animal into an eye of the dystrophic recipient. Herein disclosed is the first successful and stable integration of clonally derived ACSC into same-species but different strain recipients (e. g., Fischer rat-derived adult hippocampal derived progenitor cells (AHPCs) into dystrophic RCS rats). Surprisingly, AHPCs were also found to integrate successfully into a xenogeneic recipient (e.g., rat AHPCs into the retina of dystropic rd-I mice).
Patent no: 6,428,787 titled ‘TNF inhibitors for the treatment of retinal disorders’ with the abstract : A method is disclosed for inhibiting the action of TNF for treating conditions of the optic nerve or retina in a human by administering a TNF antagonist for reducing the inflammation of neuronal tissue, or for modulating the immune response affecting neuronal tissue of a human by administering to the human a therapeutically effective dosage level of a TNF antagonist. The TNF antagonist is selected from the group consisting of etanercept, infliximab, pegylated soluble TNF receptor Type I (PEGsTNF-R1), CDP571 (a humanized monoclonal anti-TNF-alpha antibody), and D2E7 (a human anti-TNF mAb) for reducing the inflammation of neuronal tissue of a human, or for modulating the immune response affecting neuronal tissue of a human.
Patent no: 6,310,093 titled ‘Method of preventing neuronal death’ with the abstract : Disclosed is a method for preventing neuronal cell death subsequent to an injury to neuronal tissue, particularly central nervous tissue exposed to an ischemic or hypoxic event, to trauma or to a chronic neurodegenerative disorder. The method includes exposing the cells to a glutaminase inhibitor that is relatively impermeant to healthy, intact cell membranes, and which is preferably a specific inhibitor of the form of glutaminase that is widely present in brain tissue.
Patent no: 6,340,668 titled ‘Neuronal uses of BMP-11’ with the abstract: Purified BMP-11 proteins and processes for producing them are disclosed. Recombinant DNA molecules encoding the BMP-11 proteins are also disclosed. The proteins may be useful in regulating follicle stimulating hormone, such as for contraception. In addition, the proteins may be useful for the induction and/or maintenance of bone, cartilage and/or other connective tissue, and/or neuronal tissue.
Join Free Patent Lessons Course
